Neogen's post-3M Food Safety integration shows tentative stabilization, with gross margin recovering roughly 900 basis points from the 38.8% trough in 2025Q2 to 47.8% in 2026Q4 and revenue posting 6.5% growth in 2027Q1 after seven consecutive quarters of decline.
Price trend, volume and key moving averages
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 6, 2026 | $0.08+50.0% vs $0.05 | $223M+7.0% vs $208M |
Q3 2026 Jul 30, 2026 | $0.09+58.8% vs $0.06 | $225M+6.1% vs $212M |
Q2 2026 Apr 9, 2026 | $0.09+125.0% vs $0.04 | $211M+3.3% vs $204M |
Q1 2026 Jan 8, 2026 | $0.10+42.9% vs $0.07 | $225M+8.2% vs $208M |
Neogen beats Where Food Comes From in revenue growth and recovery potential, but higher debt and integration risks complicate the food safety stock showdown.
Neogen Corporation (NASDAQ: NEOG - Get Free Report) has been assigned a consensus recommendation of "Hold" from the five analysts that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average
Here, we highlight three medical product stocks, ICUI, NEOG and TRLV, which are well positioned to benefit from industry tailwinds and could be worth adding to investors' portfolios.
I believe Neogen's recurring food safety products provide a foundation for its operating recovery. However, management has to execute carefully and proceed with the Petrifilm transition, which, if successful, should improve its cash flows long-term. Also, NEOG's recent genomics sale should give it extra flexibility, but we have to wait and see until we know how much its earnings may decrease as a result.
Benchmark NEOG against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Neogen Corporation (NEOG)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $11.76 | $2.56B | -45.71 | -2.71% | -6.35% | -2.68% | — | |
| $676.04 | $53.33B | 45.20 | 10.42% | 25.36% | 71.18% | — | |
| $21.79 | $700.87M | 12.06 | 41.03% | 32.34% | 10.08% | 0.46% | |
| $10.70 | $729.64M | -1.99 | -1.89% | -14.24% | -20.13% | — | |
| $10.78 | $1.77B | -23.17 | 64.69% | -18.64% | — | — | |
| $381.57 | $10.27B | 10.05 | 0.65% | 39.45% | 14.07% | — |
Neogen Corporation (NEOG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Neogen Corporation (NEOG) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 7, 2026·SEC
Oct 6, 2026·SEC
Jul 30, 2026·SEC
Get notified when NEOG posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Neogen Corporation (NEOG) stock FAQ — growth, dividends, profitability & financials explained
Neogen Corporation (NEOG) reported $884.0M in revenue over the trailing twelve months. Revenue was $870.4M in fiscal year 2026. That is 5589% more than the $15.3M of fiscal year 1997.
Neogen Corporation (NEOG) revenue fell by 0.3% over the trailing twelve months, compared with the twelve months before.
No. Neogen Corporation (NEOG) reported a net loss of $56.1M over the trailing twelve months.
Neogen Corporation (NEOG) had a return on equity (ROE) of -2.7% over the trailing twelve months. A negative ROE means the company lost money over the period.
Neogen Corporation (NEOG) generated $49.7M in free cash flow over the trailing twelve months.
